Enhanced disease reduction using clozapine, an atypical antipsychotic agent, and glatiramer acetate combination therapy in experimental autoimmune encephalomyelitis.

ABSTRACT:

Background

Atypical antipsychotic agents (AAP) alleviate the symptoms of severe mental health disorders, such as schizophrenia, by antagonizing dopamine and serotonin receptors. Recently, AAP have also been shown to exhibit immunomodulatory properties in the central nervous system (CNS).

Objective

Building on research which demonstrated the ability of the AAP risperidone and clozapine to modify the disease course of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), we aimed to more fully investigate the potential of clozapine as a possible treatment for MS.

Results

We report that orally administered clozapine significantly reduced the disease severity of EAE in a dose-dependent manner and was effective when administered proph

SUBMITTER: Green LK 

PROVIDER: S-EPMC5453410 | biostudies-literature | 2017 Jan-Mar

REPOSITORIES: biostudies-literature